Generated by AI
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing mental health treatments. The company concentrates on rapid-acting, durable, and convenient therapies designed to address difficult-to-treat psychiatric conditions, including depression, treatment-resistant depression, social anxiety disorder, and other central nervous system disorders. Its current pipeline includes investigational programs based on psychedelic-inspired and neuroplasticity-driven compounds, developed through internal research and strategic collaborations. AtaiBeckley Inc. also works across discovery, clinical development, and potential commercialization activities, reflecting its role in advancing new therapeutic options within the mental health and neuroscience markets. Headquartered in New York, AtaiBeckley Inc. operates as part of the broader biotechnology and pharmaceutical sector, where it is known for targeting unmet needs in mental health care with a specialized, research-focused portfolio.
Website250 West 34th Street
New York, NY, 10119
United States
Summary of Sep 15's posts. Generated by AI.
Summary of Jul 16's posts. Generated by AI.
Summary of Jul 16's posts. Generated by AI.
Summary of Sep 14's posts. Generated by AI.
Investors talking about ATAI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.